Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL

Circulation. 2021 Nov 23;144(21):1732-1734. doi: 10.1161/CIRCULATIONAHA.121.056536. Epub 2021 Aug 27.

Authors

Nicholas A Marston¹, Robert P Giugliano¹, Jeong-Gun Park¹, Andrea Ruzza², Peter S Sever³, Anthony C Keech⁴, Marc S Sabatine¹

Affiliations

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (N.A.M., R.P.G., J.-G.P., M.S.S.).
² Amgen, Thousand Oaks, CA (A.R.).
³ National Heart and Lung Institute, Imperial College London, United Kingdom (P.S.S.).
⁴ Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.).

No abstract available

Keywords: cholesterol; coronary artery disease; lipids; lipoproteins, LDL; therapeutics.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers*
Cardiovascular Diseases / blood
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / etiology
Cardiovascular Physiological Phenomena*
Cardiovascular System / metabolism*
Cholesterol, LDL / blood*
Health Impact Assessment
Humans
Public Health Surveillance

Substances

Biomarkers
Cholesterol, LDL

Grants and funding

K08 HL153950/HL/NHLBI NIH HHS/United States